Patients who develop AF while being treated with BRAF inhibitor/MEK inhibitor should be managed in accordance with standard cardiology guidelines, although caution is required when considering anticoagulation, as concurrent treatment with MEK inhibitors66, 67, 68 and certain BRAF inhibitors64 may be associated with an increased risk of bleeding. This evidence concerns the gene MAP2K7 and atrial fibrillation.